ライフサイエンスコーパス: fecal occult blood

1 ds that were processed for the evaluation of fecal occult blood.

2 h advanced neoplasia had a positive test for fecal occult blood.

3 oscopy for fecal leukocytes nor an assay for fecal occult blood, alone or in combination, allowed for

4 Both annual testing for fecal occult blood and biennial testing significantly re

5 In addition to currently available methods (fecal occult blood, flexible sigmoidoscopy, colonoscopy,

6 lines for colorectal cancer recommend annual fecal occult blood (FOB) testing for adults aged 50 year

7 Hemoccult II, a widely used guaiac test for fecal occult blood, has a low sensitivity for detecting

8 of gastric ulcers, and a higher incidence of fecal occult blood loss.

9 vide better screening compliance compared to fecal occult blood or endoscopic screening.

10 =300 pg/ml (odds ratio [OR]: 7.3), positive fecal occult blood (OR: 13.2), hemoglobin < or =90 g/l (

11 evaluation of hematochezia (19%) or positive fecal occult blood test (15%).

12 primary care providers use only the digital fecal occult blood test (FOBT) as their primary screenin

13 screening test for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with l

14 The use of the fecal occult blood test (FOBT) for colorectal cancer (CR

15 (HR, 1.38; 95% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) t

16 6.26, 165.19), or having undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29)

17 barriers (for example, simplifying access to fecal occult blood test cards), or made system-level cha

18 5% ethanol, RNAlater Stabilization Solution, fecal occult blood test cards, and fecal immunochemical

19 detect early cancer include sensitive guaiac fecal occult blood test or fecal immunochemical test.

20 ith diagnostic indications, such as positive fecal occult blood test result (OR, 0.33; 95% CI, 0.19-0

21 l studies, these guidelines recommend annual fecal occult blood test screening plus periodic flexible

22 eral, persons who have positive results on a fecal occult blood test should have a full colonic exami

23 of colonoscopy, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 100

24 ed for colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48%

25 ed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test,

26 prove the sensitivity and specificity of the fecal occult blood test.

27 Combined one-time screening with a fecal occult-blood test and sigmoidoscopy identified 75.

28 l DNA in stool samples with the Hemoccult II fecal occult-blood test in average-risk, asymptomatic pe

29 the sensitivity of one-time screening with a fecal occult-blood test plus sigmoidoscopy.

30 One-time screening with both a fecal occult-blood test with rehydration and sigmoidosco

31 ysis (40%), blood glucose measurement (41%), fecal occult blood testing (39%), and chest radiography

32 for screening by fecal DNA testing (F-DNA), fecal occult blood testing (FOBT) and/or sigmoidoscopy,

33 covered mammography, Papanicolaou tests, and fecal occult blood testing (FOBT) but not colonoscopy, f

34 spent per year of life saved), using annual fecal occult blood testing (FOBT) combined with flexible

35 as colonoscopy or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, co

36 oidoscopy plus either sensitive unrehydrated fecal occult blood testing (FOBT) or fecal immunochemica

37 strategy for white men was annual rehydrated fecal occult blood testing (FOBT) plus sigmoidoscopy (fo

38 more likely to have negative attitudes about fecal occult blood testing (FOBT), but not about flexibl

39 tion of once-only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

40 ery 10 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immuno

41 unds of biennial screening with guaiac-based fecal occult blood testing (n = 419,966) showed reduced

42 re needed to improve patient compliance with fecal occult blood testing and colorectal cancer screeni

43 domized clinical trials to reduce mortality: fecal occult blood testing and flexible sigmoidoscopy.

44 Combining fecal occult blood testing and sigmoidoscopy may decreas

45 creened with sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colon

46 he unscreened population within 1 year using fecal occult blood testing followed by diagnostic colono

47 mination screening every 3 years plus annual fecal occult blood testing had an ICER of more than $100

48 mily history of colon cancer and had not had fecal occult blood testing in the past year or flexible

49 Fecal occult blood testing is a popular screening test b

50 false positives and high false negatives of fecal occult blood testing lead to high costs and low co

51 r the cancer was detected by screening using fecal occult blood testing or evaluation of symptoms.

52 Fecal occult blood testing or flexible sigmoidoscopy was

53 mining diagnostic yield supported the use of fecal occult blood testing plus sigmoidoscopy.

54 once at age 65) or the combination of annual fecal occult blood testing with sigmoidoscopy every 5 ye

55 y are reasonable substitutes for traditional fecal occult blood testing, although modeling may be nee

56 ndomized trials support the use of screening fecal occult blood testing, and case-control studies sup

57 Screening with sensitive guaiac-based fecal occult blood testing, fecal immunochemical testing

58 pared favorably with reported performance of fecal occult blood testing, flexible sigmoidoscopy, and

59 every 3 years, or every 5 years with annual fecal occult blood testing, had an ICER of less than $55

60 reening have illustrated efficacy, including fecal occult blood testing, sigmoidoscopy and colonoscop

61 ng appears to be lower than that with guaiac fecal occult blood testing.

62 anicolaou smears, cholesterol screening, and fecal occult blood testing.

63 apacity exists for widespread screening with fecal occult blood testing.

64 data relevant to optimizing the technique of fecal occult blood testing.

65 Fecal occult-blood testing and sigmoidoscopy have been r

66 bjects returned the three specimen cards for fecal occult-blood testing and underwent a complete colo

67 Although fecal occult-blood testing is the only available noninva

68 The effect of screening with fecal occult-blood testing on colorectal-cancer mortalit

69 In randomized trials, fecal occult-blood testing reduces mortality from colore

70 The use of either annual or biennial fecal occult-blood testing significantly reduces the inc

71 ens on cards from three consecutive days for fecal occult-blood testing, which were rehydrated for in

72 rol) or to annual or biennial screening with fecal occult-blood testing.

73 Rates of patient completion of fecal occult blood tests (FOBTs) are often low.

74 Consecutive rounds of fecal occult blood tests (FOBTs) are used to screen for

75 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy

76 , 95% confidence interval (CI): 1.17, 2.19), fecal occult blood tests (HR=1.31, 95% CI: 1.12, 1.53),

77 When used for screening, fecal occult blood tests have positive results about 1%

78 Screening for colorectal cancer with fecal occult blood tests or sigmoidoscopy can reduce mor

79 e Services Task Force endorse screening with fecal occult blood tests or sigmoidoscopy.

80 opy, 178 healthy women aged 70-74 years with fecal occult blood tests, 431 women aged 75-79 years in

81 ing health status using 3 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5

82 ides information that can be used to perform fecal occult blood tests, interpret the results of those

83 A number of screening tests, including fecal occult blood tests, sigmoidoscopy, double-contrast

84 show better performance characteristics than fecal occult blood tests.

85 men aged 80-84 years in average health with fecal occult blood tests.

86 ntestinal bleeding, as evidenced by positive fecal occult blood tests.

87 for age-matched men and women with negative fecal occult-blood tests and no family history of colon

88 In a group of patients with positive fecal occult-blood tests who were referred for further e

89 an cause a positive reaction on guaiac-based fecal occult-blood tests, the relative frequency of uppe

90 A set of three fecal occult-blood tests--Hemoccult II; Hemoccult II Sen

91 ed with subjects who had a negative test for fecal occult blood, the relative risk of advanced neopla

92 Fecal occult blood was detected by standard guaiac-based

93 with at least one stool specimen containing fecal occult blood who were referred for further evaluat

94 Of the 409 patients with fecal occult blood who were referred, 310 were potential